• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Withdrawal Versus Continuation of Thiopurine in Vedolizumab-Treated Patients With Ulcerative Colitis (VIEWS): A Multi-Centre Randomised Controlled Trial.维多珠单抗治疗的溃疡性结肠炎患者硫嘌呤的撤药与继续用药（VIEWS）：一项多中心随机对照试验
Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):11-12.
2
Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial.硫唑嘌呤停药对溃疡性结肠炎接受维得利珠单抗治疗患者的影响：一项随机对照试验。
Clin Gastroenterol Hepatol. 2024 Nov;22(11):2299-2308.e5. doi: 10.1016/j.cgh.2024.04.019. Epub 2024 May 9.
3
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With Vedolizumab Professor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota.特别会议回顾版：欧洲克罗恩病和结肠炎组织（ECCO）第14届大会炎症性肠病亮点：对第14届欧洲克罗恩病和结肠炎组织（ECCO）大会部分演讲的回顾 • 2019年3月6 - 9日 • 丹麦哥本哈根• VARSITY：维多珠单抗与阿达木单抗治疗活动性溃疡性结肠炎患者的双盲、双模拟、随机对照试验• 来自VISIBLE 1和2试验的数据分析：维多珠单抗治疗溃疡性结肠炎或克罗恩病患者• 乌帕替尼作为中度至重度活动性溃疡性结肠炎成人诱导治疗的内镜结果改善和黏膜愈合：U - ACHIEVE研究数据• 维多珠单抗治疗溃疡性结肠炎和克罗恩病的长期安全性：GEMINI LTS研究最终结果• 儿童克罗恩病阿达木单抗基于水平的优化治疗（PAILOT）随机对照试验• 抗P19导向的IL - 23抗体mirikizumab维持治疗：中度至重度活动性溃疡性结肠炎患者52周结果• 维多珠单抗和抗TNF治疗在初治溃疡性结肠炎或克罗恩病患者中的真实世界有效性和安全性：EVOLVE研究结果• 靶向释放口服环孢素制剂治疗轻至中度溃疡性结肠炎的随机、多中心、双盲、安慰剂对照研究：疗效结果• 接受维多珠单抗治疗的炎症性肠病患者的真实世界分析 医学教授 胃肠病学和肝病科 梅奥诊所 明尼苏达州罗切斯特
Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 2):1-24.
4
Vedolizumab for induction and maintenance of remission in ulcerative colitis.维多珠单抗用于溃疡性结肠炎的诱导缓解和维持缓解
Cochrane Database Syst Rev. 2014 Aug 8;2014(8):CD007571. doi: 10.1002/14651858.CD007571.pub2.
5
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.英夫利昔单抗与维得利珠单抗治疗炎症性肠病患者的疗效和安全性比较：系统评价和荟萃分析。
BMC Gastroenterol. 2022 Jun 8;22(1):291. doi: 10.1186/s12876-022-02347-1.
6
Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis.影响溃疡性结肠炎患者生物治疗停药的因素。
J Pharm Health Care Sci. 2024 Oct 18;10(1):65. doi: 10.1186/s40780-024-00386-2.
7
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.Filgotinib 作为溃疡性结肠炎的诱导缓解和维持治疗（SELECTION）：一项 2b/3 期双盲、随机、安慰剂对照试验。
Lancet. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3.
8
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.维多珠单抗对溃疡性结肠炎患者健康相关生活质量的影响：随机GEMINI 1试验的结果
Aliment Pharmacol Ther. 2017 Jan;45(2):264-275. doi: 10.1111/apt.13852. Epub 2016 Nov 17.
9
Efficacy of optimised thiopurine therapy in patients with moderate-to-severe ulcerative colitis: retrospective long-term follow-up from two randomised trials.优化的硫嘌呤治疗中重度溃疡性结肠炎患者的疗效：两项随机试验的回顾性长期随访。
Scand J Gastroenterol. 2024 Jun;59(6):669-673. doi: 10.1080/00365521.2024.2323502. Epub 2024 Mar 5.
10
Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling.使用马尔可夫模型评估维多珠单抗在日本溃疡性结肠炎治疗模式中的最佳位置。
Crohns Colitis 360. 2020 Mar 18;2(2):otaa017. doi: 10.1093/crocol/otaa017. eCollection 2020 Apr.

引用本文的文献

1
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis.维多珠单抗在溃疡性结肠炎中的长期疗效及持续使用的预测因素
Therap Adv Gastroenterol. 2024 Jul 30;17:17562848241258372. doi: 10.1177/17562848241258372. eCollection 2024.
2
Highlights in Ulcerative Colitis From Digestive Disease Week 2023: Commentary.2023年消化系统疾病周溃疡性结肠炎亮点：评论
Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):13-16.

本文引用的文献

1
Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.与维多珠单抗单药治疗相比，维多珠单抗与硫唑嘌呤联合治疗克罗恩病时治疗失败风险降低。
Gut. 2022 Sep;71(9):1781-1789. doi: 10.1136/gutjnl-2022-327002. Epub 2022 Apr 6.
2
No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.炎症性肠病患者中，联合免疫调节剂治疗对非肿瘤坏死因子拮抗剂生物制剂疗效无益处：一项荟萃分析。
Clin Gastroenterol Hepatol. 2021 Apr;19(4):668-679.e8. doi: 10.1016/j.cgh.2020.06.071. Epub 2020 Jul 3.

Withdrawal Versus Continuation of Thiopurine in Vedolizumab-Treated Patients With Ulcerative Colitis (VIEWS): A Multi-Centre Randomised Controlled Trial.

出版信息

Gastroenterol Hepatol (N Y). 2023 Jul;19(7 Suppl 3):11-12.

PMID:38445003
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10910367/
Abstract
摘要